



5TH World Congress of Cutaneous Lymphomas

*Enhancing the Ability to Diagnose, Interpret and Apply
Best Treatment Options for Cutaneous Lymphomas*

April 11 to 13, 2024

Pasadena Convention Center
Pasadena, California, U.S.



2024 CONGRESS PROGRAM

5TH WORLD CONGRESS OF CUTANEOUS LYMPHOMAS IS HONORED TO WELCOME



TABLE OF CONTENTS

CONGRESS AT A GLANCE.....	2
CONTACTS.....	4
GUEST LECTURES	5
FACULTY	6
SPECIAL ACKNOWLEDGMENTS	7
GENERAL INFORMATION	8
CME INFORMATION.....	10
E-SYLLABUS	11
WI-FI	12
SOCIAL GATHERINGS.....	13
UPCOMING CME SYMPOSIA.....	14
SPONSORSHIP ACKNOWLEDGMENT.....	15
ACKNOWLEDGMENT OF EXHIBIT SUPPORT.....	16
INDUSTRY SATELLITE SYMPOSIA	17
PROGRAM AT A GLANCE	19
CONGRESS SCHEDULE	22
MEDIA LOUNGE/DIGITAL TWIN.....	33
POSTERS.....	34
INDUSTRY SATELLITE SYMPOSIA	36
INDUSTRY ADVERTISEMENTS.....	37
ABSTRACT PRESENTER INDEX	41

An aerial photograph of Pasadena, California, taken at dusk. The sky is a mix of soft pinks, oranges, and blues, with wispy clouds. The city below is illuminated with warm lights from buildings and street lamps. A prominent feature is the large, ornate building with a dark dome and classical architectural details, likely the Pasadena City Hall. Other buildings of various styles, including modern multi-story structures and older, more traditional ones, are visible. Palm trees and other greenery are scattered throughout the urban landscape. The overall atmosphere is serene and welcoming.

Welcome to
PASADENA



5TH World Congress of Cutaneous Lymphomas

*Enhancing the Ability to Diagnose, Interpret and Apply
Best Treatment Options for Cutaneous Lymphomas*

April 11 to 13, 2024

Pasadena Convention Center | Pasadena, CA



This activity is brought to you in collaboration with ISCL
(International Society for Cutaneous Lymphomas).

CONGRESS HIGHLIGHTS INCLUDE

- Lectures and scientific abstracts on pathology, genetics, tumor microenvironment, therapeutics, clinical studies, quality of life and leading-edge research in cutaneous lymphomas
- Debates and discussions on key controversies
- Interactive question and answer sessions
- Poster sessions
- Networking opportunities among clinicians, investigators and scientists across institutions and geographical borders

CONGRESS AT A GLANCE

DAY ONE


6:30 to 7:45 a.m.	Registration/Breakfast/Exhibits/Posters	Ballroom DE
6:45 to 7:45 a.m.	Sanofi Breakfast Satellite Symposium	Ballroom C
7:45 a.m. to 5:35 p.m.	General Session	Ballroom F-H
10:20 a.m. to 5:05 p.m.	Breakout Sessions	Ballroom B
12:45 to 1:45 p.m.	Lunch/Exhibits/Posters	Ballroom DE
12:45 to 1:45 p.m.	Helsinn Lunch Satellite Symposium	Ballroom C
1:45 to 2:45 p.m.	Poster/Exhibit Reception	Ballroom DE
5:35 p.m.	Day One Sessions Adjourn	
6 to 8 p.m.	Congress Welcome Reception	The Westin Pasadena Courtyard

DAY TWO

6:45 to 7:35 a.m.	ISCL Board of Directors Meeting	Ballroom A
6:45 to 7:40 a.m.	Registration/Breakfast/Exhibits/Posters	Ballroom DE
7:40 a.m. to 5 p.m.	General Session	Ballroom F-H
7:50 a.m. to 5 p.m.	Breakout Sessions	Ballroom B
11:45 a.m. to 12:45 p.m.	Lunch/Exhibits/Posters	Ballroom DE
11:45 a.m. to 12:45 p.m.	Kyowa Kirin Lunch Satellite Symposium	Ballroom C
11:45 a.m. to 12:45 p.m.	USCLC Board of Directors Meeting	Ballroom A
3 to 5 p.m.	EORTC Board of Directors Meeting	Ballroom A
5 p.m.	Day Two Sessions Adjourn	
6 p.m.	Shuttle to Congress Gala Dinner Preregistration and Prepaid Ticket Required. No on-site purchases.	

DAY THREE

7 to 7:30 a.m.	Registration/Breakfast/Exhibits/Posters	Ballroom DE
7:30 to 8 a.m.	ISCL Assembly Meeting <i>(NON-CME ACCREDITED)</i>	Ballroom F-H
8 a.m. to 12:35 p.m.	General Session	Ballroom F-H
8 to 10:25 a.m.	Breakout Sessions	Ballroom B
12:35 p.m.	Congress Adjourns/Lunch	
1:30 p.m.	Shuttle to The Huntington Library/Preregistration Required	



Congress Host Hotel

The Westin Pasadena


191 N. Los Robles Ave., Pasadena, CA 91101



Congress Venue

Pasadena Convention Center

300 E. Green Street, Pasadena, CA 91101



Pasadena Convention Center

Floor Plan

CONGRESS CO-CHAIRS



Christiane Querfeld, MD, PhD

Director, Cutaneous Lymphoma Program
Professor, Departments of Pathology,
Hematology & Surgery
Division of Dermatology
City of Hope, United States (U.S.)



Emilia Hodak, MD

President, International Society for
Cutaneous Lymphomas (ISCL)
Director, Cutaneous Lymphoma Service
Professor, Davidoff Cancer Center
Rabin Medical Center, Israel

DEAR FRIENDS AND COLLEAGUES,

On behalf of the 5th World Congress of Cutaneous Lymphomas (WCCL) Organizing Committee and the International Society for Cutaneous Lymphomas (ISCL), it is a great pleasure to welcome you to the 5th WCCL in Pasadena, California, U.S., on April 11 to 13, 2024!

Following four highly successful congresses in Chicago 2010, Berlin 2013, New York 2016 and Barcelona 2020, the 5th World Congress in Pasadena presents a wonderful opportunity to share experiences, to exchange scientific ideas and foster interactions between physicians, researchers and all involved in the field of cutaneous lymphomas. The program provides an innovative and comprehensive overview of the state-of-the-art advances in basic, translational and clinical research; it discusses new developments in the diagnosis, practice and management of cutaneous lymphomas, promoting the highest standards of care and support of the patients.

The 5th WCCL provides a premier interdisciplinary platform for all participants (basic scientists, dermatologists, hematologists, clinical oncologists, dermatopathologists, radiation oncologists and others) not only to share the updates and the most recent advances, but also discuss practical challenges in the field of cutaneous lymphomas.

Pasadena is a city that, much like the WCCL, inspires innovation. It is Southern California's "shiny jewel" which, like this year's Congress logo, is artfully layered and culturally rich — inspired by the Tournament of Roses annual parade of flower-covered floats held in this city since 1890. Pasadena is a local scene with global offerings and mouth-watering cuisine. We invite you to visit the Explore Pasadena page!

cme.CityofHope.org/content/explore-pasadena

Welcome to the 5th World Congress of Cutaneous Lymphomas in Pasadena!

JOIN THE ISCL!

We encourage you to join the International Society for Cutaneous Lymphomas, the organizing society of the World Congress of Cutaneous Lymphomas. The ISCL is dedicated to the treatment, research and caring of patients with cutaneous lymphomas. The ISCL was founded in 1992 at the World Congress of Dermatology in New York and among its aims are to increase knowledge of lymphoproliferative and related disorders of the skin, foster collaboration among clinicians and scientists, and promote dissemination of scientific information.

To apply for membership, please complete the application form at the following link:

cutaneouslymphoma.org



CONTACTS

SCIENTIFIC PLANNING COMMITTEE

Emmilia Hodak, MD, Co-Chair | Israel
Christiane Querfeld, MD, PhD, Co-Chair | U.S.
Martine Bagot, MD, PhD | France
Jaehyuk Choi, MD, PhD | U.S.
Paula Enz, MD | Argentina
Larisa J. Geskin, MD | U.S.
Michael Girardi, MD | U.S.
Robert Gniadecki, MD, PhD | Canada
Emmanuella Guenova, MD, PhD | Switzerland
Steven M. Horwitz, MD | U.S.
Tomomitsu Miyagaki, MD, PhD | Japan
Jan Nicolay, MD, MSc | Germany
Pablo L. Ortiz-Romero, MD, PhD | Spain
H. Miles Prince AM, MBBS (Hons), MD | Australia
Pietro Quaglino, MD | Italy
Jose Antonio Sanches Junior, MD, PhD | Brazil
Julia Scarisbrick, MBChB, MD | United Kingdom
Yang Wang, MD | China

LOCAL ORGANIZING AND SCIENTIFIC COMMITTEE

Emmilia Hodak, MD, Co-Chair
Christiane Querfeld, MD, PhD, Co-Chair
Victoria Ceh, MPA, ISCL Executive Director
Niloufer Khan, MD, MSCE
Michael Khodadoust, MD, PhD
Youn H. Kim, MD
Steven T. Rosen, MD
Crystal Saavedra, BA
Jasmine Zain, MD

FUNDRAISING COMMITTEE

Christiane Querfeld, MD, PhD, Co-Chair
Larisa J. Geskin, MD
Joan Guitart, MD | U.S.
Steven M. Horwitz, MD
Youn H. Kim, MD
Steven T. Rosen, MD
Jasmine Zain, MD

ISCL HEADQUARTERS

1932 S. Halsted Street, Suite 413
Chicago, IL 60608 U.S.
+1-630-578-3991

EXECUTIVE DIRECTOR: Victoria Ceh, MPA
info@cutaneouslymphoma.org
cutaneouslymphoma.org

ISCL BOARD OF DIRECTORS

PRESIDENT: Emmilia Hodak, MD
SECRETARY: Julia Scarisbrick, MBChB, MD
TREASURER: Steven M. Horwitz, MD
IMM-PAST PRESIDENT: Larisa J. Geskin, MD

Antonio Cozzio, MD, PhD | Switzerland
Jade Cury-Martins, MD, PhD | Brazil
Paula Enz, MD
Alejandro A. Gru, MD | U.S.
Michael Khodadoust, MD, PhD
Youn H. Kim, MD
Ivan V. Litvinov, MD, PhD | Canada
Tomomitsu Miyagaki, MD, PhD
Montserrat Molgo, MD | Chile
Pablo L. Ortiz-Romero, MD, PhD
Evangelia Papadavid, MD, PhD | Greece
Lauren C. Pinter-Brown, MD | U.S.
Barbara Pro, MD | U.S.
Ramon M. Pujol, MD, PhD | Spain
Christiane Querfeld, MD, PhD
Rudolf Stadler, MD, PhD | Germany
Yang Wang, MD

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) CUTANEOUS LYMPHOMA TUMOUR GROUP

CHAIR: Evangelia Papadavid, MD, PhD
SECRETARY: Emmanuella Guenova, MD, PhD
TREASURER: Maxime Battistella, MD, PhD
IMM-PAST CHAIR: Julia Scarisbrick, MBChB, MD

EORTC HEADQUARTERS

Avenue Emmanuel Mounier 83/11
1200 Brussels, Belgium

UNITED STATES CUTANEOUS LYMPHOMA CONSORTIUM (USCLC) BOARD OF DIRECTORS

PRESIDENT: Alejandro A. Gru, MD
SECRETARY-TREASURER: Larisa J. Geskin, MD
IMM-PAST PRESIDENT: Francine M. Foss, MD
Oleg E. Akilov, MD, PhD
Stefan K. Barta, MD, MS
Anne Beaven, MD
Kimberly Bohjanen, MD
Auris Huen, MD, PharmD
Mary Jo Lechowicz, MD
Aaron Mangold, MD
Amy Musiek, MD
Stefan M. Schieke, MD
Michi Shinohara, MD
Peggy Wu, MD
REGISTRY CO-CHAIRS: Elise A. Olsen, MD, and Joi Carter, MD

USCLC HEADQUARTERS

701 Bradford Ave., Nashville, TN 37204 U.S.
1-615-460-1662
usclc.org

ZACKHEIM LECTURE



Wing C. (John) Chan, MD

Professor, Department of Pathology
Dr. Norman & Melinda Payson Professor
in Hematologic Cancers
City of Hope

The Herschel Zackheim Lectureship was established to honor Herschel Zackheim (1914-2009), MD, a clinical professor emeritus at University of California San Francisco, who pioneered the discovery of treatments for patients with cutaneous lymphoma. The lectureship recognizes and honors a clinician and/or researcher who has been a significant contributor to advancing the science and understanding of lymphoma-related biology, has contributed research that has or will be expected to improve treatment for lymphoma patients, and has outstanding leadership qualities.

Building Human Peripheral T-Cell Lymphoma Models for Biological and Therapeutic Investigations

Thursday, April 11, 2024

12:10 to 12:45 p.m.

Ballroom F-H

PLENARY LECTURE



L. Elizabeth Budde, MD, PhD

Associate Professor
Department of Hematology &
Hematopoietic Cell Transplantation
Executive Medical Director
Enterprise Immune Effector
Cell Program
City of Hope

Advances & Limitations of CAR T-Cell Therapy

Friday, April 12, 2024

12:45 to 1:20 p.m.

Ballroom F-H

*Enhancing the Ability to Diagnose, Interpret and Apply
Best Treatment Options for Cutaneous Lymphomas*



FACULTY

PRIMARY CHAIRS AND CO-CHAIRS

Wei Ai, MD, PhD | U.S.
Oleg E. Akilov, MD, PhD | U.S.
Pamela Blair Allen, MD, MSc | U.S.
Florent Amatore, MD, PhD | France
Iris Amitay-Laish, MD | Israel
Martine Bagot, MD, PhD | France
Stefan K. Barta, MD, MS | U.S.
Aviv Barzilai, MD, MSc | Israel
Emilio Berti, MD | Italy
Patrick M. Brunner, MD, MSc | U.S.
Jaehyuk Choi, MD, PhD | U.S.
Richard Cowan, MD | United Kingdom
Antonio Cozzio, MD, PhD | Switzerland
Jade Cury-Martins, MD, PhD | Brazil
Gabor Dobos, MD, PhD | Germany
Paula Enz, MD | Argentina
Larisa J. Geskin, MD | U.S.
Michael Girardi, MD | U.S.
Alejandro A. Gru, MD | U.S.
Joan Guitart, MD | U.S.
Brad Haverkos, MD | U.S.
Emmilia Hodak, MD | Israel
Steven M. Horwitz, MD | U.S.
Auris Huen, MD, PharmD | U.S.
Constanze Jonak, MD | Austria
Werner Kempf, MD | Switzerland
Niloufer Khan, MD, MSCE | U.S.
Michael Khodadoust, MD, PhD | U.S.
Youn H. Kim, MD | U.S.
Ellen J. Kim, MD | U.S.
Cecilia Larocca, MD | U.S.
Ivan V. Litvinov, MD, PhD | Canada
Christopher McCormack, MBBS | Australia
Christina Mitteldorf, MD | Germany
Tomomitsu Miyagaki, MD, PhD | Japan
Kevin Molloy, MB, PhD | Ireland
Amy Musiek, MD | U.S.
Jan Nicolay, MD, MSc | Germany
Neda Nikbakht, MD, PhD | U.S.
Elise A. Olsen, MD | U.S.
Evangelia Papadavid, MD, PhD | Greece
Laura Pincus, MD | U.S.
Pierluigi Porcu, MD | U.S.
H. Miles Prince AM, MBBS (Hons), MD | Australia
Pietro Quaglino, MD | Italy
Christiane Querfeld, MD, PhD | U.S.
Kerri E. Rieger, MD, PhD | U.S.
Steven T. Rosen, MD | U.S.
Sima Rozati, MD, PhD | U.S.
Jose Antonio Sanches Junior, MD, PhD | Brazil
Julia Scarisbrick, MBChB, MD | United Kingdom
Stefan M. Schieke, MD | U.S.
Michi Shinohara, MD | U.S.
Rudolf Stadler, MD, PhD | Germany
Makoto Sugaya, MD, PhD | Japan
Cornelis P. Tensen, PhD | Netherlands
Maarten Vermeer, MD, PhD | Netherlands
Yang Wang, MD | China
Sean Whittaker, MD | United Kingdom
Ryan A. Wilcox, MD, PhD | U.S.
Jasmine Zain, MD | U.S.

ADDITIONAL FACULTY

Idoroenyi Amanam, MD | U.S.
Kimlin Tam Ashing, PhD | U.S.
Chalid Assaf, MD, PhD | Germany
L. Elizabeth Budde, MD, PhD | U.S.
Wing C. (John) Chan, MD | U.S.
Francine M. Foss, MD | U.S.
Robert Gniadecki, MD, PhD | Canada
Emmanuella Guenova, MD, PhD | Switzerland
Swami P. Iyer, MBBS, MD | U.S.
Matt Lunning, DO | U.S.
Pablo L. Ortiz-Romero, MD, PhD | Spain
Wen-Kai Weng, MD, PhD | U.S.

AWARD PRESENTERS

Emmilia Hodak, MD | ISCL 2024 Travel Scholarship Awards and ISCL 2024 Lifetime Achievement Awards
Susan Thornton, CEO Cutaneous Lymphoma Foundation | CLF Young Investigator Awards

SPECIAL ACKNOWLEDGMENTS


PATIENTS

We would like to extend our most sincere gratitude to the patients who have made themselves available to participate in the Quality of Life/Patient-Reported Outcomes session for their valuable time, insight and vulnerability.

Quality of Life Patient Testimonials

Moderated by Niloufer Khan, MD, MSCE

Friday, April 12, 2024 | 4:30 to 5 p.m. | Ballroom B



Briana Castellanos



Michaeldiamond E. McGee



Joseph Odundo Okeyo

ISCL 2024 LIFETIME ACHIEVEMENT AWARDEES

Join us as the ISCL Lifetime Achievement Awardees are recognized for their outstanding contribution to the science and care of patients with cutaneous lymphomas.

Award Session

Friday, April 12, 2024 | 11:35 to 11:45 a.m. | Ballroom F-H



Martine Bagot, MD, PhD



Richard L. Edelson, MD



Alain H. Rook, MD



Gary S. Wood, MD

GENERAL INFORMATION

CONTACTLESS REGISTRANT SIGN-IN

You must confirm your attendance **daily** at the conference.

During the conference, you will be provided with a unique code to record your attendance. You will need to submit the attendance code to the City of Hope CME online submission portal. Registrant sign-in will be facilitated via QR code, therefore, please ensure you bring your cell phone with you.

TO ENSURE YOU ARE READY FOR CONTACTLESS REGISTRANT SIGN-IN:

1. Please be sure to have with you the cell phone (mobile) you registered in your CME Profile.
2. Using your mobile phone, please log on now to: <https://cme.CityofHope.org/code>. You will see where you will enter the code (this is just so you get familiar with the online submission portal).
 - a. Exit the browser without logging out. This step will facilitate the recording of your attendance while at the conference, as you will not need to log back in.
3. Please ensure your cell phone is fully charged, as charging stations will not be available in the conference area.



MEETING MATERIALS

Check in at the registration desk to receive conference materials and a name badge.

CONGRESS NAME BADGE

Official conference name badge must be worn at all times to gain and maintain access to conference room and meals.

CONFERENCE LOCATION

Pasadena Convention Center
300 East Green Street
Pasadena, CA 91101

EDUCATIONAL SESSIONS

General Session: Ballroom F-H
Breakout Sessions: Ballroom B

REGISTRATION DESK — HOURS OF OPERATION

DATE	TIME	LOCATION
Thursday, April 11	6:30 a.m. to 5:35 p.m.	Ballroom Entry
Friday, April 12	6:45 a.m. to 5 p.m.	Ballroom Entry
Saturday, April 13	7 a.m. to 12:35 p.m.	Ballroom Entry

CONFERENCE MEALS AND BREAKS

DATE	DESCRIPTION	TIME	LOCATION
Thursday, April 11	Breakfast	6:30 to 7:45 a.m.	Ballroom DE
Thursday, April 11	Refreshment Break	10:20 to 10:40 a.m.	Ballroom DE
Thursday, April 11	Lunch	12:45 to 1:45 p.m.	Ballroom DE
Thursday, April 11	Poster/Exhibit Reception	1:45 to 2:45 p.m.	Ballroom DE
Thursday, April 11	Congress Welcome Reception	6 to 8 p.m.	The Westin Pasadena Courtyard
Friday, April 12	Breakfast	6:45 to 7:40 a.m.	Ballroom DE
Friday, April 12	Refreshment Break	10:10 to 10:30 a.m.	Ballroom DE
Friday, April 12	Lunch	11:45 a.m. to 12:45 p.m.	Ballroom DE
Friday, April 12	Refreshment Break	2:40 to 3 p.m.	Ballroom DE
Friday, April 12	Congress Gala Dinner <i>Prepaid Ticket Required</i>	7 to 10 p.m.	Off-Site Location
Saturday, April 13	Breakfast	7 to 7:30 a.m.	Ballroom DE
Saturday, April 13	Refreshment Break	10:25 to 10:45 a.m.	Ballroom DE
Saturday, April 13	Lunch	12:35 p.m.	Ballroom DE

EXHIBIT AND POSTER HALL HOURS

DATE	TIME	LOCATION
Thursday, April 11	6:30 to 7:45 a.m.; 10:20 to 10:40 a.m.; 12:45 to 1:45 p.m.; 1:45 to 2:45 p.m.	Ballroom DE
Friday, April 12	6:45 to 7:40 a.m.; 10:10 to 10:30 a.m.; 11:45 a.m. to 12:45 p.m.; 2:40 to 3 p.m.	Ballroom DE
Saturday, April 13	7 to 7:30 a.m.; 10:25 to 10:45 a.m.	Ballroom DE

CME INFORMATION

ACCREDITATION STATEMENT

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION STATEMENT

City of Hope designates this live activity for a maximum of 19.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the educational activity.

The following may apply *AMA PRA Category 1 Credit™* for license renewal:

- **Registered Nurses:** Nurses may report up to 19.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.
- **Physician Assistants:** The National Commission on Certification of Physician Assistants states that *AMA PRA Category 1 Credit™* accredited courses are acceptable for continuing medical education requirements for recertification.

DISCLOSURE

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity. Faculty and planners have provided written disclosure of all relevant financial relationships, which have been included in this handout. Any potential conflicts relative to the disclosure(s) have been resolved. City of Hope further encourages faculty/presenters to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

INSTRUCTIONS FOR OBTAINING CME CREDIT (*AMA PRA Category 1 Credit™*)

Participants seeking to claim CME credit must complete the following steps:

1. Submit the unique attendance code to the City of Hope CME System (facilitated via QR code).
2. Complete and submit the evaluation that will be emailed to the registered email address. CME Certificates will be accessible online upon submission of the conference evaluation.

FOR MORE INFORMATION

Contact the City of Hope Department of Continuing Medical Education at cme@coh.org.

To ensure that you are receiving the most current slide sets presented, as well as keeping with City of Hope's "green initiative" to reduce waste, an e-syllabus containing slide sets is available for this activity online only (printed presentation not available on-site). We recommend you access available presentations prior to the conference and bring your computer or mobile device fully charged. We gratefully acknowledge the presenters for their permission to offer this material as an e-syllabus.

E-SYLLABUS DOWNLOAD/PRINTING INSTRUCTIONS:

(printed syllabus will not be provided on-site)

If you would like to download or print a copy of available presentations simply:

1. Visit the appropriate link(s) below (Oral Presentations and/or Poster Presentations).
2. Find the desired presentation and click on the title of the presentation you would like to download.
3. The presentation will open and appear in PDF format.
4. To save the presentation, click "Save As."
5. To print the presentation, click "Print."

AJCC Cancer Staging Forms

- Access to the AJCC Cancer Staging Forms is also available via the e-syllabus.

5WCCL | E-SYLLABUS

<https://cme.cityofhope.org/content/5wccl-e-syllabus>

PLEASE NOTE:

- Some presentations not provided prior to the conference will be accessible postactivity.
- Presentations will be available for four weeks following the conclusion of this educational activity.
- Presentations have been uploaded at the discretion of each faculty member.

*Enhancing the Ability to Diagnose, Interpret and Apply
Best Treatment Options for Cutaneous Lymphomas*



WI-FI

Daily dedicated bandwidth will be provided by Encore, ensuring that participants have a seamless connection and can access the e-syllabus and presentations to follow along.

Wi-Fi generously sponsored by



Network: 5thWorldCongress

Password: WCCL2024

City of Hope gratefully acknowledges the generous sponsorship from Encore.

We look forward to attendees participating in the 5th World Congress of Cutaneous Lymphomas' social gatherings, where participants will be able to network, collaborate with colleagues and create new connections and opportunities for collaboration.

OFFICIAL CONGRESS-ISSUED BADGE MUST BE WORN FOR ALL ACTIVITIES.

Please Note: Some activities require preregistration/prepaid tickets.



CONGRESS WELCOME RECEPTION

Thursday, April 11, 2024
6 to 8 p.m.

*Complimentary for
Registered Attendee*

CONGRESS GALA DINNER

Friday, April 12, 2024
7 to 10 p.m.

*Cocktail Attire
Paid Ticket Required*

THE HUNTINGTON LIBRARY CURATOR-LED DISCUSSION*

Saturday, April 13, 2024
2 to 5 p.m.

*Limited to 50 Attendees
Preregistration Required*

**Join curator Joel A. Klein, PhD, for a behind-the-scenes show and tell with treasures from The Huntington Library's collection of rare medical texts. Participants will be free to explore the gardens and exhibitions from 3 to 5 p.m.*

SHUTTLE SERVICE

Shuttle service will be provided for ticketed attendees for the Congress Gala Dinner and The Huntington Library Curator-Led Discussion.

UPCOMING CME SYMPOSIA

Scan QR code for additional information.



 City of Hope.

Interdisciplinary End of Life Symposium

MAY 29 TO 31, 2024 | PARK MGM LAS VEGAS



 City of Hope.

 SIO Integrative Oncology

21st International Conference of the Society for Integrative Oncology

October 25 to 27, 2024
The Westin South Coast Plaza | Costa Mesa, California, U.S.



 City of Hope.

Multidisciplinary Approaches to Cancer Symposium

November 7 to 9, 2024
Turtle Bay Resort | O'ahu, Hawaii

Early Bird Registration Available! 



SPONSORSHIP ACKNOWLEDGMENT

5TH World Congress of
Cutaneous Lymphomas

CITY OF HOPE AND ISCL GRATEFULLY ACKNOWLEDGE THE GENEROUS SPONSORSHIP FROM:

DIAMOND SPONSOR



GOLD SPONSORS



SILVER SPONSOR



ADDITIONAL SPONSORS INCLUDE



ACKNOWLEDGMENT OF EXHIBIT SUPPORT

CITY OF HOPE AND ISCL GRATEFULLY ACKNOWLEDGE THE GENEROUS SUPPORT FROM:




INDUSTRY SATELLITE SYMPOSIA

INDUSTRY SATELLITE SYMPOSIA IS NON-CME ACCREDITED

The following sessions will be held during breakfast/lunch (as indicated) in Ballroom C.

Please pick up food in Ballroom DE and head straight to Ballroom C in a timely manner, so as to not interrupt the presentation in progress.



REZUROCK[®]
(belumosudil) tablets

**Could REZUROCK hit the
right note for your patients?**

**Join Amandeep Salhotra, MD,
for a closer look at REZUROCK.**

Thursday, April 11, 2024

6:45 AM to 7:45 AM

Ballroom C

PRODUCT THEATER



Guest Lecturer: Oleg E. Akilov, MD, PhD

**University of Pittsburgh
Assistant Professor**

**Director, Cutaneous Lymphoma Program
and Extracorporeal Photopheresis Unit**



Date

Thursday, April 11, 2024



Time

12:45 PM - 1:45 PM



Location

Pasadena Convention Center
Ballroom C
300 East Green Street
Pasadena, CA 91101

This program is for healthcare professionals only.

This is a promotional program sponsored by Helsinn Therapeutics (U.S.), Inc. This is not a Continuing Medical Education (CME) program. In accordance with the PhRMA code on Interactions with Healthcare Professionals, attendance at this educational program is limited to healthcare professionals. Accordingly, attendance by guests or significant others is not permitted. Due to state law restrictions, healthcare professionals practicing in Vermont are not eligible to receive complimentary food or beverages during the presentation. Additional federal or state restrictions may apply.

VALCHLOR[®] is a trademark of Helsinn Birex Pharmaceuticals Ltd., Ireland. VALCHLOR[®] is distributed and marketed by Helsinn Therapeutics (U.S.), Inc. under license.

© 2024 Helsinn Therapeutics (U.S.), Inc. All rights reserved. V-VALC-US-0452 0224



Kyowa Kirin Presents

Dodging the Pitfalls of Diagnosing Cutaneous T-cell Lymphoma (CTCL)

A non-CME symposium being presented at the 2024 World Congress of Cutaneous Lymphomas

Friday, April 12, 2024 • 11:45 AM – 12:45 PM

Ballroom C



Featured speaker:

Alejandro A. Gru, MD

*Leonard C. Harber Professor of Dermatology
Director of Dermatopathology
Columbia University Irving Medical Center*

Speaker is a paid consultant of Kyowa Kirin.

Join us as **Dr. Gru**, a specialist in dermatopathology, shares his insights on **CTCL pathogenesis** and the steps towards accurate diagnosis.

PROGRAM AT A GLANCE

THURSDAY, APRIL 11, 2024

TIME	GENERAL SESSION BALLROOM F-H	BREAKOUT SESSION BALLROOM B	BALLROOM C
6:30 to 7:45 a.m.	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS		SANOFI BREAKFAST SATELLITE SYMPOSIUM <i>An Innovative Treatment Option for Appropriate Patients with cGVHD</i> Amandeep Salhotra, MD (NON-CME ACCREDITED)
7:45 to 8 a.m.	Welcome & Announcements		
8 to 10:20 a.m.	Session A CLASSIFICATION/EPIDEMIOLOGY/ PROGNOSTIC FACTORS Primary Chair: Joan Guitart, MD Co-Chairs: Jose Antonio Sanches Junior, MD, PhD ; Laura Pincus, MD ; Elise A. Olsen, MD		
10:20 to 10:40 a.m.	REFRESHMENT BREAK/EXHIBITS/POSTERS		
10:40 to 11:40 a.m.	CLASSIFICATION/EPIDEMIOLOGY/ PROGNOSTIC FACTORS Primary Chair: Emilio Berti, MD Co-Chairs: Christina Mitteldorf, MD ; Kerri E. Rieger, MD, PhD		Session B CUTANEOUS LYMPHOMA INTERNATIONAL CONSORTIUM – PROCLIPI STUDIES Primary Chair: Julia Scarisbrick, MBChB, MD Co-Chairs: Larisa J. Geskin, MD ; Jade Cury-Martins, MD, PhD
11:40 a.m. to 12:10 p.m.	Primary Chair: Emilia Hodak, MD Co-Chairs: Alejandro A. Gru, MD ; Youn H. Kim, MD ; Larisa J. Geskin, MD ; Werner Kempf, MD		
12:10 to 12:45 p.m.	Zackheim Lecture Building Human Peripheral T-Cell Lymphoma Models for Biological and Therapeutic Investigations Wing C. (John) Chan, MD		
12:45 to 1:45 p.m.	LUNCH/EXHIBITS/POSTERS		HELSENN LUNCH SATELLITE SYMPOSIUM <i>Treating Stage IA/IB MF-CTCL: Reviewing Recent Clinical Data</i> Oleg E. Akilov, MD, PhD (NON-CME ACCREDITED)
1:45 to 2:45 p.m.	POSTER/EXHIBIT RECEPTION		
2:45 to 5:35 p.m.	Session C BIOLOGIC INSIGHTS Primary Chair: Jaehyuk Choi, MD, PhD Co-Chairs: Sean Whittaker, MD ; Michael Girardi, MD ; Cornelis P. Tensen, PhD ; Ivan V. Litvinov, MD, PhD		Session D PATHOGENESIS/BIOMARKERS Primary Chair: Maarten Vermeer, MD, PhD Co-Chairs: Jan Nicolay, MD, MSc ; Tomomitsu Miyagaki, MD, PhD ; Stefan M. Schieke, MD ; Aviv Barzilaj, MD, MSc
5:35 p.m.	CLOSING REMARKS/ADJOURN DAY ONE		
6 to 8 p.m.	CONGRESS WELCOME RECEPTION THE WESTIN PASADENA COURTYARD		

FRIDAY, APRIL 12, 2024

TIME	GENERAL SESSION BALLROOM F-H	BREAKOUT SESSION BALLROOM B	BOARD MEETINGS BALLROOM A
6:45 to 7:35 a.m.			ISCL Board of Directors Meeting
6:45 to 7:40 a.m.	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS		
7:40 to 7:50 a.m.	Welcome & Announcements (BALLROOM F-H) AWARD SESSION ISCL Travel Scholarships (Emmilia Hodak, MD) and CLF Young Investigator Awards (Susan Thornton)		
7:50 to 10:10 a.m.	Session E TUMOR MICROENVIRONMENT Primary Chair: Christiane Querfeld, MD, PhD Co-Chairs: Neda Nikbakht, MD, PhD; Gabor Dobos, MD, PhD; Florent Amatore, MD, PhD	Session F THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: Martine Bagot, MD, PhD Co-Chairs: Wei Ai, MD, PhD; Antonio Cozzio, MD, PhD; Christopher McCormack, MBBS	
10:10 to 10:30 a.m.	REFRESHMENT BREAK/EXHIBITS/POSTERS		
10:30 to 11:35a.m.	TUMOR MICROENVIRONMENT Primary Chair: Patrick M. Brunner, MD, MSc Co-Chair: Evangelia Papadavid, MD, PhD	THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: Steven M. Horwitz, MD Co-Chair: Steven T. Rosen, MD	
11:35 to 11:45 a.m.	AWARD SESSION: ISCL 2024 Lifetime Achievement Awards (BALLROOM F-H)		
11:45 a.m. to 12:45 p.m.	LUNCH/EXHIBITS/POSTERS	KYOWA KIRIN LUNCH SATELLITE SYMPOSIUM (BALLROOM C) <i>Dodging the Pitfalls of Diagnosing Cutaneous T-Cell Lymphoma (CTCL)</i> Alejandro A. Gru, MD (NON-CME ACCREDITED)	USCLC Board of Directors Meeting
12:45 to 1:20 p.m.	Plenary Lecture Advances & Limitations of CAR T-Cell Therapy L. Elizabeth Budde, MD, PhD		
1:20 to 2:40 p.m.	Session G THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: Michael Khodadoust, MD, PhD Co-Chairs: Ryan A. Wilcox, MD, PhD; Rudolf Stadler, MD, PhD; Jasmine Zain, MD	Session H QUALITY OF LIFE/PATIENT-REPORTED OUTCOMES Primary Chair: Kevin Molloy, MB, PhD Co-Chairs: Pamela Blair Allen, MD, MSc; Amy Musiek, MD	
2:40 to 3 p.m.	REFRESHMENT BREAK/EXHIBITS/POSTERS		
3 to 5 p.m.	THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: H. Miles Prince AM, MBBS (Hons), MD Co-Chairs: Pierluigi Porcu, MD; Richard Cowan, MD; Brad Haverkos, MD; Auris Huen, MD, PharmD	QUALITY OF LIFE/PATIENT-REPORTED OUTCOMES Primary Chair: Michi Shinohara, MD Co-Chairs: Constanze Jonak, MD; Ellen J. Kim, MD; Niloufer Khan, MD, MSCE; Cecilia Larocca, MD	EORTC Board of Directors Meeting
5 p.m.	CLOSING REMARKS/ADJOURN DAY TWO		
6 to 7 p.m.	SHUTTLE FROM HOST HOTEL TO CONGRESS GALA DINNER Shuttle sponsored by Kyowa Kirin		
7 to 10 p.m.	CONGRESS GALA DINNER <i>Not included in congress registration. Paid ticket is required.</i>		
10 to 10:30 p.m.	SHUTTLE FROM CONGRESS GALA DINNER TO HOST HOTEL Shuttle sponsored by Kyowa Kirin		

SATURDAY, APRIL 13, 2024

TIME	GENERAL SESSION BALLROOM F-H	BREAKOUT SESSION BALLROOM B
7 to 7:30 a.m.	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS	
7:30 to 8 a.m.	ISCL ASSEMBLY MEETING (NON-CME ACCREDITED)	
8 to 8:05 a.m.	Welcome & Announcements	
8:05 to 10:25 a.m.	Session I CHALLENGING CASES OF CUTANEOUS LYMPHOMAS Primary Chair: Pietro Quaglino, MD Co-Chairs: Stefan K. Barta, MD, MS; Iris Amitay-Laish, MD; Paula Enz, MD	Session J LEADING-EDGE RESEARCH AND FUTURE DIRECTIONS OF CUTANEOUS LYMPHOMAS Primary Chair: Oleg E. Akilov, MD, PhD Co-Chairs: Yang Wang, MD; Sima Rozati, MD, PhD; Makoto Sugaya, MD, PhD
10:25 to 10:45 a.m.	REFRESHMENT BREAK/EXHIBITS/POSTERS	
10:45 a.m. to 12:35 p.m.	Debate: Epidermotropic Cutaneous T-Cell Lymphoma with Gamma-delta Phenotype: Is it Mycosis Fungoides or Gamma-delta T-Cell Lymphoma? Cutaneous T-Cell Lymphoma Jeopardy Best of Congress	
12:35 p.m.	CLOSING REMARKS/ADJOURN CONGRESS AND LUNCH	
1:30 p.m.	SHUTTLE FROM PASADENA CONVENTION CENTER TO THE HUNTINGTON LIBRARY Shuttle sponsored by CRISPR Therapeutics	
2 to 5 p.m.	THE HUNTINGTON LIBRARY <i>Not included in congress registration. Preregistration/ticket is required.</i>	
5:15 p.m.	SHUTTLE FROM THE HUNTINGTON LIBRARY TO HOST HOTEL Shuttle sponsored by CRISPR Therapeutics	

Enhancing the Ability to Diagnose, Interpret and Apply Best Treatment Options for Cutaneous Lymphomas



CONGRESS SCHEDULE

DAY 1/THURSDAY, APRIL 11, 2024

GENERAL SESSION | BALLROOM F-H

6:30 to 7:45 a.m.	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS BALLROOM DE
7:45 to 8 a.m.	<p>Welcome & Announcements</p> <p>SESSION A CLASSIFICATION/EPIDEMIOLOGY/PROGNOSTIC FACTORS</p> <p>Primary Chair: Joan Guitart, MD</p> <p>Co-Chairs: Jose Antonio Sanches Junior, MD, PhD; Laura Pincus, MD; Elise A. Olsen, MD</p>
8 to 8:20 a.m.	Overview & Updates in the Classification of Cutaneous Lymphomas Joan Guitart, MD
8:20 to 10:20 a.m.	<p>A-01 The Modified TNMB Staging Criteria Fail to Identify Sézary Syndrome Patients with Low Blood Burden Lauren Chrisman, BA</p> <p>A-02 Clinical Consequences of Reclassifying of Low-grade Malignant Cutaneous Lymphomas as Cutaneous Lymphoproliferative Disorders Rein Willemze, MD</p> <p>A-03 Cutaneous Intravascular Lymphoproliferations: A Proposal for a Diagnostic Algorithm Brandy Phan, BSA</p> <p>A-04 Racial Differences in the Skin Microbiome of Cutaneous T-Cell Lymphoma Patients Yanzhen (Janet) Pang, BS</p> <p>A-05 The Impact of Lymph Node Clonality Status in the Prognosis of Mycosis Fungoides and Sézary Syndrome Denis Miyashiro, MD, PhD</p> <p>A-06 The Role of Bone Marrow Biopsies in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma Sima Rozati, MD, PhD</p> <p>A-07 Chronic Inflammatory Comorbidities in Primary Cutaneous Marginal Zone Lymphoma: Identifying the Underlying Cause William Nguyen, BS</p> <p>A-08 Overlapping Diagnostic Criteria in Lymphomatoid Papulosis – A Prospective Multicenter Study On 141 Biopsy Specimens Christina Mitteldorf, MD</p> <p>A-09 Prognostic Factors for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Multicenter Retrospective Study From Japan Tomomitsu Miyagaki, MD, PhD</p> <p>A-10 Pediatric Cutaneous Lymphomas Including Rare Subtypes: A 40-Year Experience at a Tertiary Referral Center Silvia Alberti-Violetti, MD, PhD</p> <p>A-11 Long Term Outcomes of Juvenile-onset Mycosis Fungoides Rishabh Lohray, BS</p> <p>A-12 Clinical Characteristics and Outcome of Hypopigmented Mycosis Fungoides: A Retrospective Multicenter Study Jongbin Park, MD, PhD</p>
10:20 to 10:40 a.m.	<p>REFRESHMENT BREAK/EXHIBITS/POSTERS</p> <p>Primary Chair: Emilio Berti, MD</p> <p>Co-Chairs: Christina Mitteldorf, MD; Kerri E. Rieger, MD, PhD</p>
10:40 to 11:40 a.m.	<p>A-13 Curing Advanced-Stage Mycosis Fungoides/ Sézary Syndrome Seda Purnak, MD</p> <p>A-14 Patterns of Care in Cutaneous T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) Prospective Cohort Study Pamela Blair Allen, MD, MSc</p> <p>A-15 Primary Cutaneous Lymphomas/Lymphoproliferative Disorders with T-Follicular Helper Phenotype: A Tertiary Cancer Center Experience Ziba Rahbar, MD, MPH</p> <p>A-16 T-Follicular Helper Immunophenotype in Mycosis Fungoides and Sézary Syndrome: A Clinico-Pathological Analysis of 33 Cases Emilio Berti, MD</p> <p>A-17 Reactive T- and B-Cell Rich Lymphoid Proliferations – Spectrum and Subtypes Werner Kempf, MD</p>
11:40 a.m. to 12:10 p.m.	<p>Primary Chair: Emilia Hodak, MD</p> <p>Co-Chairs: Alejandro A. Gru, MD; Youn H. Kim, MD; Larisa J. Geskin, MD; Werner Kempf, MD</p> <p>Standardization of Clinical and Pathologic Reports of Mycosis Fungoides/Sézary Syndrome</p> <p>Emilia Hodak, MD (Clinical) and Alejandro A. Gru, MD (Pathology)</p>
12:10 to 12:45 p.m.	<p>Zackheim Lecture</p> <p>Building Human Peripheral T-Cell Lymphoma Models for Biological and Therapeutic Investigations</p> <p>Wing C. (John) Chan, MD</p>

BREAKOUT SESSION | BALLROOM B

SANOBI BREAKFAST SATELLITE SYMPOSIUM | BALLROOM C (6:45 to 7:45 a.m.)

An Innovative Treatment Option for Appropriate Patients With cGVHD [Amandeep Salhotra, MD](#) *NON-CME ACCREDITED*

SESSION B | CUTANEOUS LYMPHOMA INTERNATIONAL CONSORTIUM — PROCLIPI STUDIES

Primary Chair: [Julia Scarisbrick, MBChB, MD](#) | Co-Chairs: [Larisa J. Geskin, MD](#); [Jade Cury-Martins, MD, PhD](#)

Update on PROCLIPI International Efforts

[Julia Scarisbrick, MBChB, MD](#)

Harnessing the Power of Machine Learning and AI for Collaborative Clinical-Pathological Genomic Integration: ISCL Initiative

[Larisa J. Geskin, MD](#)

B-01 Identifying Patients at Risk of Disease Progression & Poorer Outcomes: Results from the PROCLIPI Study

[Julia Scarisbrick, MBChB, MD](#)

B-02 Response Rates, Response Duration, and TTNT in Advanced Stage Mycosis Fungoides/Sézary Syndrome Patients from the PROCLIPI study [Pietro Quaglino, MD](#)

B-03 Prognostic Implications of Lesional Body Surface Area in Early-stage Mycosis Fungoides

[Juliette Kersten, MD](#)

DAY 1/THURSDAY, APRIL 11, 2024 CONT.

GENERAL SESSION | BALLROOM F-H

12:45 to 1:45 p.m.	LUNCH/EXHIBITS/POSTERS
1:45 to 2:45 p.m.	<p>POSTER/EXHIBIT RECEPTION</p> <p>SESSION C BIOLOGIC INSIGHTS</p> <p>Primary Chair: Jaehyuk Choi, MD, PhD</p> <p>Co-Chairs: Sean Whittaker, MD; Michael Girardi, MD; Cornelis P. Tensen, PhD; Ivan V. Litvinov, MD, PhD</p>
2:45 to 3:05 p.m.	<p>Genomic Characterization of Cutaneous Lymphomas</p> <p>Jaehyuk Choi, MD, PhD</p>
3:05 to 5:05 p.m.	<p>C-01 Molecular Profiling of Skin Lesions from a Patient with Angioimmunoblastic T-Cell Lymphoma in Comparison to Tumor-stage Mycosis Fungoides Reveals Disease-specific Markers Emry Cohenour, MS</p> <p>C-02 Clinical-Pathologic Characterization of Gene-Fusion Positive Cutaneous T-Cell Lymphoma Cases Liam Donnelly, MD</p> <p>C-03 Aberrant Serine Phosphorylation of STAT3 in Sézary Syndrome Victoria Campbell, MSci, Mres</p> <p>C-04 Unraveling the Role of HDAC10 in the Molecular Background of Sézary Syndrome Monika Pieniawska, MSc</p> <p>C-05 Tracing the Evolutionary Origins and Transcriptomic Variability in Sézary Syndrome and Mycosis Fungoides Simon Cao, MPH</p> <p>C-06 Characterization of Genomic Changes in Large Cell Transformed Mycosis Fungoides and Sézary Syndrome Jennifer Wang, MD</p> <p>C-07 Exploring the Role of Clonal T-LGL Proliferations in Cutaneous T-Cell Lymphoma Yumeng (Julia) Zhang, MD</p> <p>C-08 MHC-I Upregulation Safeguards Neoplastic T-Cells in the Skin Against NK Cell-mediated Eradication in Mycosis Fungoides Yun-Tsan Chang, PhD</p> <p>C-09 Next Generation Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Rebekah Wieland, MD, MS</p> <p>C-10 Bexarotene-induced Upregulation of Siglec-7 and Siglec-9 on Peripheral Blood T-Cells: A Potential Therapeutic Target Miki Kume, MD, PhD</p>
5:05 to 5:35 p.m.	<p>DEBATE: The Origin of Mycosis Fungoides: Blood vs. Skin</p> <p><i>Moderator: Emmanuella Guenova, MD, PhD</i></p> <p>Robert Gniadecki, MD, PhD (Blood) and Michael Girardi, MD (Skin)</p>
5:35 p.m.	CLOSING REMARKS/ADJOURN DAY ONE
6 to 8 p.m.	CONGRESS WELCOME RECEPTION THE WESTIN PASADENA COURTYARD

BREAKOUT SESSION | BALLROOM B

HELSINN LUNCH SATELLITE SYMPOSIUM | BALLROOM C

Treating Stage IA/IB MF-CTCL: Reviewing Recent Clinical Data [Oleg E. Akilov, MD, PhD](#)

NON-CME ACCREDITED

SESSION D | PATHOGENESIS/BIOMARKERS

Primary Chair: Maarten Vermeer, MD, PhD

Co-Chairs: Jan Nicolay, MD, MSc; Tomomitsu Miyagaki, MD, PhD; Stefan M. Schieke, MD; Aviv Barzilai, MD, MSc

Phenotypic and Molecular Biomarkers in Cutaneous Lymphomas

[Maarten Vermeer, MD, PhD](#)

- D-01 **Detection of Multiple Clonal TCR Rearrangements in Cutaneous T-Cell Lymphoma by TCR Clonality by High-throughput Sequencing**
[Joseph Cleveland, MD](#)
- D-02 **High-throughput Sequencing of the T-Cell Receptor β and γ Gene Correlates with Aggressive Subtypes of Mycosis Fungoides and Sézary Syndrome and Immune Checkpoint Expression** [Liliana Crisan, MD](#)
- D-03 **Novel Potential Marker for Sézary Syndrome Diagnosis: TMEM244 Gene**
[Karolina Rassek, PhD](#)
- D-04 **TYK2 Rearranged Primary Cutaneous T-Cell Lymphoma with Novel Presentations**
[Melissa Pulitzer, MD](#)
- D-05 **Progression-associated Genome Alterations in EZH1/2 Revealed by Multi-omic Studies in Cutaneous T-Cell Lymphoma**
[Jacqueline Payton, MD, PhD](#)
- D-06 **Unleashed Monocytic Engagement in Sézary Syndrome During the Combination of Anti-CCR4 Antibody with Type I Interferon**
[Oleg E. Akilov, MD, PhD](#)
- D-07 **Integrated Transcriptomics Reveals Cellular and Molecular Interactions in Pruritic Cutaneous T-Cell Lymphoma**
[Andrea Roggo, MD](#)
- D-08 **Cellular and Molecular Profiling of Mycosis Fungoides and Primary Cutaneous CD30+ Lymphoproliferative Disorders Reveal Factors Associated with Indolent vs. Aggressive Clinical Behavior**
[Katharina Rindler, PhD](#)
- D-09 **Erythroderma from Cutaneous T-Cell Lymphoma Exhibits a Different Microbial and Proteomic Profile from Erythroderma Caused by Benign Etiologies** [Yanzhen \(Janet\) Pang, BS](#)
- D-10 **Single-cell RNA Sequencing of Primary Cutaneous T-Cell Lymphomas with a CD4, CD8 or TCR-gamma/delta Clonal Phenotype Identifies Subset-specific Biomarkers**
[Sumanth Chennareddy, BA](#)

DAY TWO/FRIDAY, APRIL 12, 2024

GENERAL SESSION | BALLROOM F-H

6:45 to 7:40 a.m.	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS BALLROOM DE
7:40 – 7:50 a.m.	<p>Welcome & Announcements</p> <p>AWARD SESSION: Emmilia Hodak, MD ISCL Travel Scholarships & Susan Thornton CLF Young Investigator Awards</p> <p>SESSION E TUMOR MICROENVIRONMENT Primary Chair: Christiane Querfeld, MD, PhD Co-Chairs: Neda Nikbakht, MD, PhD; Gabor Dobos, MD, PhD; Florent Amatore, MD, PhD</p>
7:50 to 8:10 a.m.	The Role of the Tumor Microenvironment Christiane Querfeld, MD, PhD
8:10 to 10:10 a.m.	<p>E-01 Single Cell Proteomic Analysis Defines a Deferential Exhausted Phenotype in Tumor Microenvironment with Mycosis Fungoides Progression Evangelia Papadavid, MD, PhD</p> <p>E-02 Langerhans Cell Population Expands Early after Immune Checkpoint Inhibition in the Microenvironment of Mycosis Fungoides Duncan Murray, MBChB, PhD</p> <p>E-03 Enhancing Anti-tumor Immunity by Targeting miR-146a and miR-21 in Mycosis Fungoides with Large-cell Transformation Zhen Han, PhD</p> <p>E-04 The Microenvironment in Transformed Mycosis Fungoides: Increased NKG2A and its Role as a Potential Therapeutic Target Pamela Blair Allen, MD, MSc</p> <p>E-05 Recombinant CD155 Promotes Tumor Cell Proliferation as well as IL-13 Expression in Cutaneous T-Cell Lymphoma Ryoma Honda, MD</p> <p>E-06 OX-40 Promotes Tumor Progression in Cutaneous T-Cell Lymphoma by Regulating ERK Activation Evangelia Papadavid, MD, PhD</p> <p>E-07 Total Skin Electron Beam Radiation Therapy is Associated with Enriched Cutaneous Microbial Diversity in Cutaneous T-Cell Lymphoma Madeline J. Hooper, MD</p> <p>E-08 Cutaneous T-Cell Lymphoma Tumors Undergoing Radiation Demonstrate Shifts in Transcriptional Landscape from Malignant Inflammation to Wound Healing and Tissue Remodeling Lauren Chrisman, BA</p> <p>E-09 Differences in the Spatially Resolved Transcriptome Profiles Leading to Progression in Mycosis Fungoides Woo Jin Lee, MD, PhD</p>
10:10 to 10:30 a.m.	<p>REFRESHMENT BREAK/EXHIBITS/POSTERS Primary Chair: Patrick M. Brunner, MD, MSc Co-Chair: Evangelia Papadavid, MD, PhD</p>
10:30 to 11:05 a.m.	<p>E-10 M2 Macrophages in the Cutaneous Microenvironment of Mycosis Fungoides and Sézary Syndrome and their Impact on Lymph Node Involvement Daniel Montezzo, MD, PhD</p> <p>E-11 Tumor Promoting Activity of Toll-like Receptor 4 in the Cutaneous T-Cell Lymphoma Microenvironment Neda Nikbakht, MD, PhD</p> <p>E-12 scRNA-Seq Reveals Differential Gene Expression of Cancer-associated Fibroblast Markers in Mycosis Fungoides by Stage and Race Courtney M. Johnson, MD, PhD</p>
11:05 to 11:35 a.m.	<p>DEBATE: Allogeneic Transplant in Advanced Stage Disease: How Early Should We Do It in the Disease Course? Early vs. Late <i>Moderator: Francine M. Foss, MD</i> Swami P. Iyer, MBBS, MD (Early) and Wen-Kai Weng, MD, PhD (Late)</p>
11:35 to 11:45 a.m.	AWARD SESSION: Emmilia Hodak, MD ISCL 2024 Lifetime Achievement Awards
11:45 a.m. to 12:45 p.m.	LUNCH/EXHIBITS/POSTERS

BREAKOUT SESSION | BALLROOM B

ISCL BOARD OF DIRECTORS (BOD) MEETING | BALLROOM A (6:45 to 7:35 a.m.)

SESSION F | THERAPEUTICS/PRECLINICAL STUDIES

Primary Chair: Martine Bagot, MD, PhD

Co-Chairs: Wei Ai, MD, PhD; Antonio Cozzio, MD, PhD; Christopher McCormack, MBBS

Identifying Novel Targets for Treatment of Cutaneous T-Cell Lymphoma [Martine Bagot, MD, PhD](#)

- F-01 Targeting CDK9 in Cutaneous T-Cell Lymphoma Using Patient-derived Xenograft Models**
[Wei Ai, MD, PhD](#)
- F-02 Targeting the Non-ATP-binding Pocket of the MPA Kinase p38 γ Mediates Olfactory Receptor (OR) Directed Cytotoxicity in Cutaneous T-Cell Lymphoma**
[Xu Hannah Zhang, PhD](#)
- F-03 Investigating the Role for DNA Damage Repair (DDR) Pathway Inhibition in Sézary Syndrome**
[Farrah Bakr, MBBS, PhD](#)
- F-04 Comparison of UV-based Combination Therapies for Cutaneous T-Cell Lymphoma Cell Cultures**
[Gabor Dobos, MD, PhD](#)
- F-05 Illuminating Inequities: A Study of Narrowband UVB Therapy Response in Mycosis Fungoides Patients Across Skin Types**
[Caroline Chen, BA](#)
- F-06 Translational Data from a Multicenter Phase II Study on Dimethyl Fumarate Treatment in Relapsed and Refractory Cutaneous T-Cell Lymphoma** [Susanne Melchers, MD](#)
- F-07 Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial**
[Youn H. Kim, MD](#)
- F-08 A Phase 2 Study of Low-dose Total Skin Electron Beam Therapy (LD-TSEBT) Combined with Mogamulizumab (TSE-Moga) in Patients with Mycosis Fungoides and Sézary Syndrome**
[Ariel Karwat, BSN, MSN-AGNP](#)
- F-09 Effects of Mogamulizumab on CD39, CD73 and CD38 Ectonucleotidase Expression in CD4+/T Cells in Patients with Sézary Syndrome**
[Gabriele Rocuzzo, MD](#)
- F-10 Assessing the Efficacy of Mogamulizumab of Mycosis Fungoides and Sézary Syndrome Using Time to Next Treatment**
[Julia Scarisbrick, MBChB, MD](#)

Primary Chair: Steven M. Horwitz, MD | Co-Chair: Steven T. Rosen, MD

- F-11 RESMAIN: Results of a Multicenter, Randomized, Double Blind, Placebo-controlled Trial to Evaluate RESminostat for MAINTenance Treatment in Advanced Stage Mycosis Fungoides or Sézary Syndrome**
[Rudolf Stadler, MD, PhD](#)
- F-12 Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration by Balancing Efficacy and Tolerability** [Shamir Geller, MD](#)
- F-13 Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects with Relapsed/Refractory CD30 Positive T-Cell Lymphoma**
[Tarsheen Sethi, MD, MS](#)

KYOWA KIRIN LUNCH SATELLITE SYMPOSIUM | BALLROOM C

Dodging the Pitfalls of Diagnosing Cutaneous T-Cell Lymphoma (CTCL) [Alejandro A. Gru, MD](#)

NON-CME ACCREDITED

USCLC BOD MTG | BALLROOM A

DAY TWO/FRIDAY, APRIL 12, 2024 CONT.

GENERAL SESSION | BALLROOM F-H

12:45 to 1:20 p.m.	<p>Plenary Lecture Advances & Limitations of CAR T-Cell Therapy L. Elizabeth Budde, MD, PhD</p>
1:20 to 1:40 p.m.	<p>SESSION G THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: Michael Khodadoust, MD, PhD Co-Chairs: Ryan A. Wilcox, MD, PhD; Rudolf Stadler, MD, PhD; Jasmine Zain, MD</p>
1:40 to 2:40 p.m.	<p>The Treatment Landscape of Cutaneous T-Cell Lymphoma: Roadmap Towards Precision Medicine Michael Khodadoust, MD, PhD</p> <p>G-01 Durvalumab (Anti-PD-L1) & Lenalidomide is Superior to Single-agent Durvalumab in Refractory/Advanced Cutaneous T-Cell Lymphoma Christiane Querfeld, MD, PhD</p> <p>G-02 Mogamulizumab in Combination with Magrolimab (MoMa) in Previously Treated Mycosis Fungoides and Sézary Syndrome Michael Khodadoust, MD, PhD</p> <p>G-03 PTCL-002 Updates: Pembrolizumab in Combination with Epigenetic Therapy is Safe and Shows Activity in CTCL and PTCL Nathan Roberts, MD</p> <p>G-04 Generation and Optimization of Off-the-Shelf Immunotherapeutics Targeting TCR-Vbeta2+ T-Cell Malignancy Michael Girardi, MD</p> <p>G-05 Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Excellent Disease Control in Patients with Refractory/Relapsed Cutaneous Cytotoxic T-Cell Lymphoma Wen-Kai Weng, MD, PhD</p>
2:40 to 3 p.m.	<p>REFRESHMENT BREAK/EXHIBITS/POSTERS Primary Chair: H. Miles Prince AM, MBBS (Hons), MD Co-Chairs: Pierluigi Porcu, MD; Richard Cowan, MD; Brad Haverkos, MD; Auris Huen, MD, PharmD</p>
3 to 4 p.m.	<p>G-06 Management of Relapsed Cutaneous T-Cell Lymphoma after Allogeneic Transplantation Wen-Kai Weng, MD, PhD</p> <p>G-07 Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced CTCL: A Single-Centre Experience Including 63 Patients Francesco Onida, MD</p> <p>G-08 Allogeneic Stem Cell Transplant for Treatment of Mycosis Fungoides and Sézary Syndrome: A Systematic Review and Meta-analysis Francine M. Foss, MD</p> <p>G-09 Is Prolonged Treatment with Brentuximab an Alternative? Real-life Experience on Mycosis Fungoides/ Sézary Syndrome Patients Jade Cury-Martins, MD, PhD</p> <p>G-10 Methotrexate Single Agent and Combination Treatment in Mycosis Fungoides and Sézary Syndrome. A Multicenter, Retrospective Study Silvia Alberti-Violetti, MD, PhD</p>
4 to 5 p.m.	<p>G-11 Safety and Tolerability of E7777 (Improved Purity Denileukin Diftitox) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 H. Miles Prince AM, MBBS (Hons), MD</p> <p>G-12 Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-type (PCDLBCL-LT) in the Modern Era Tarek Bandali, MD</p> <p>G-13 Mogamulizumab Combined with Extracorporeal Photopheresis (ECP) as a Novel Therapy in Erythrodermic Cutaneous T-Cell Lymphoma Jan Nicolay, MD, MSc</p> <p>G-14 Preliminary Data of Efficacy and Tolerability of Chlormethine Gel with and without Combined Systemic Therapy – A Multicenter Retrospective Study of the German Lymphoma Group Christina Mitteldorf, MD</p> <p>G-15 Efficacy and Safety of E7777 (Improved Purity Denileukin Diftitox) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 Francine M. Foss, MD</p>
5 p.m.	CLOSING REMARKS/ADJOURN DAY TWO
6 to 7 p.m.	SHUTTLE FROM HOST HOTEL (THE WESTIN PASADENA) TO CONGRESS GALA DINNER Shuttle sponsored by Kyowa Kirin
7 to 10 p.m.	CONGRESS GALA DINNER <i>Not included in congress registration. Prepaid ticket is required.</i>
10 to 10:30 p.m.	SHUTTLE FROM CONGRESS GALA DINNER TO HOST HOTEL Shuttle sponsored by Kyowa Kirin

BREAKOUT SESSION | BALLROOM B

SESSION H | QUALITY OF LIFE/PATIENT-REPORTED OUTCOMES

Primary Chair: Kevin Molloy, MB, PhD

Co-Chairs: Pamela Blair Allen, MD, MSc; Amy Musiek, MD

Perception of Quality of Life of Patients and Treating Physicians

Kevin Molloy, MB, PhD

- H-01 **Validation and Psychometric Analysis of the Functional Assessment Cancer Therapy (FACT) – Cutaneous T-Cell Lymphoma**
Christina Asare, BS
- H-02 **First Interim Analysis of a Real-world International Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER study NCT05455931)**
Julia Scarisbrick, MBChB, MD
- H-03 **Patient Perceptions of Multi-disciplinary Teams and Healthcare Expenditure Associated with Cutaneous Lymphomas**
Michael Cao, MBBS
- H-04 **Capturing the Patient Journey using Electronic Patient-reported Outcome Measures (ePROMs) in Cutaneous B and T-Cell Lymphomas** Richard Cowan, MD
- H-05 **An Update on Health-related Quality of Life in Mycosis Fungoides/Sézary Syndrome from the PROCLIFI Study**
Kevin Molloy, MB, PhD

Primary Chair: Michi Shinohara, MD

Co-Chairs: Constanze Jonak, MD; Ellen J. Kim, MD; Niloufer Khan, MD, MSCE; Cecilia Larocca, MD

- H-06 **Principal Component Analysis and Creation of a Novel Patient-reported Outcomes Questionnaire for Patients with Cutaneous T-Cell Lymphoma** Neha Akkad, MD EORTC BOD MTG | BALLROOM A
- H-07 **Quality of Life in a Cohort of Asian Children with Mycosis Fungoides**
Mark Jean-Aan Koh, MBBS
- H-08 **A Day in the Life of a Cutaneous Lymphoma Nurse Practitioner at Peter MacCallum Cancer Centre, Melbourne, Australia**
Odette Buelens, BN, MANP-NP
- H-09 **Diagnosis of Cutaneous T-cell Lymphoma in People with Intellectual Disabilities is Delayed**
Brigit A. Lapolla, BS
- H-10 **Interim Analysis Results of an Ongoing Open-label Trial Assessing Silicone-film Forming Wound Dressing as a Steroid-sparing Supportive Therapy for CTCL-induced Pruritus**
Brigit A. Lapolla, BS

Overview of Health Inequities Issues

EORTC BOD MTG CONT. | BALLROOM A

Kimlin Tam Ashing, PhD

Idoroenyi Amanam, MD

Quality of Life Patient Testimonials

Moderator: Niloufer Khan, MD, MSCE

Briana Castellanos

Michaeldiamond E. McGee

Joseph Odundo Okeyo

DAY THREE/SATURDAY, APRIL 13, 2024

GENERAL SESSION | BALLROOM F-H

7 to 7:30 a.m.	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS BALLROOM DE
7:30 to 8 a.m.	ISCL ASSEMBLY MEETING (NON-CME ACCREDITED)
8 to 8:05 a.m.	<p>Welcome & Announcements</p> <p>SESSION I CHALLENGING CASES OF CUTANEOUS LYMPHOMAS</p> <p>Primary Chair: Pietro Quaglino, MD</p> <p>Co-Chairs: Stefan K. Barta, MD, MS; Iris Amitay-Laish, MD; Paula Enz, MD</p>
8:05 to 8:25 a.m.	Facts and Controversies in Cutaneous B-Cell Lymphomas Pietro Quaglino, MD
8:25 to 10:25 a.m.	<p>I-01 EBV Positive Primary Cutaneous Marginal Zone Lymphoma with Transformation to Plasmablastic Lymphoma Jack Reid, MD</p> <p>I-02 Brentuximab Vedotin-associated Tumor Flare Response in a Patient with Mycosis Fungoides with Large Cell Transformation Rishabh Lohray, BS</p> <p>I-03 Mogamulizumab-induced Bone Granuloma: A Multicentre Nationwide Case Series Florent Amatore, MD, PhD</p> <p>I-04 Pemphigus Foliaceus after Total Skin Electron Beam Radiation for Mycosis Fungoides Leah Cohen, MD</p> <p>I-05 Advanced Mycosis Fungoides/Sézary Syndrome Masquerading Atopic Dermatitis in the Era of Advanced Therapeutics – Clues and Pitfalls Iris Amitay-Laish, MD</p> <p>I-06 Molecular Genetic Demonstration of the Evolution of Transformed Mycosis Fungoides: A Clinicopathological and Molecular Case Study Melissa Cheng, BS</p> <p>I-07 Increased Incidence of Second Primary Malignancies in Patients with Primary Cutaneous B-Cell Lymphomas: A SEER Population Study Henry Yang, BS</p> <p>I-08 Bcl6 Expression in a T-Cell Infiltrate...Think Follicular Helper T-Cell Lymphoma Jacqueline M. Junkins-Hopkins, MD</p> <p>I-09 Co-expression of CD3 and CD20: A Clue to the Diagnosis of Intestinal Lymphoma Presenting in the Skin Nina Martins, BA</p> <p>I-10 Molecularly-annotated Case of a CD30-Positive Gamma-delta T-Cell Features of Primary Cutaneous Anaplastic Large Cell Lymphoma: A Wolf in Sheep's Clothing? Robert E. LeBlanc, MD</p> <p>I-11 Hydroa Vacciniforme-like Lymphoproliferative Disorder in a Young Asian Female Ziqi Liu, MD</p> <p>I-12 Atypical Presentation of Gamma/Delta (γ/δ) Mycosis Fungoides with an Unusual Phenotype and SOCS1 Mutation Pia Rude Nielsen, MD, PhD</p>
10:25 to 10:45 a.m.	REFRESHMENT BREAK/EXHIBITS/POSTERS
10:45 to 11:15 a.m.	<p>DEBATE: Epidermotropic Cutaneous T-Cell Lymphoma with Gamma-delta Phenotype: Is it Mycosis Fungoides or Gamma-delta T-Cell Lymphoma?</p> <p><i>Moderator: Werner Kempf, MD</i></p> <p>Alejandro A. Gru, MD (Mycosis Fungoides) and Joan Guitart, MD (Gamma-delta T-Cell Lymphoma)</p>
11:15 to 11:55 a.m.	<p>Cutaneous T-Cell Lymphoma Jeopardy</p> <p><i>Moderator: Matt Lunning, DO</i></p> <p>H. Miles Prince AM, MBBS (Hons), MD and Evangelia Papadavid, MD, PhD</p> <p>Chalid Assaf, MD, PhD and Jasmine Zain, MD</p> <p>Emmanuella Guenova, MD, PhD and Steven M. Horwitz, MD</p>
11:55 a.m. to 12:35 p.m.	<p>Best of Congress</p> <p>Youn H. Kim, MD (Therapeutics) and Pablo L. Ortiz-Romero, MD, PhD (Non-Therapeutics)</p>
12:35 p.m.	CLOSING REMARKS/ADJOURN CONGRESS AND LUNCH
1:30 p.m.	<p>SHUTTLE FROM PASADENA CONVENTION CENTER TO THE HUNTINGTON LIBRARY</p> <p>Shuttle sponsored by CRISPR Therapeutics</p>
2 to 5 p.m.	THE HUNTINGTON LIBRARY <i>Not included in congress registration. Preregistration/ticket is required.</i>
5:15 p.m.	<p>SHUTTLE FROM THE HUNTINGTON LIBRARY TO HOST HOTEL</p> <p>Shuttle sponsored by CRISPR Therapeutics</p>

SESSION J | LEADING-EDGE RESEARCH AND FUTURE DIRECTIONS OF CUTANEOUS LYMPHOMAS

Primary Chair: Oleg E. Akilov, MD, PhD

Co-Chairs: Yang Wang, MD; Sima Rozati, MD, PhD; Makoto Sugaya, MD, PhD

Multiomics in Cutaneous T-Cell Lymphoma [Oleg E. Akilov, MD, PhD](#)

- J-01 Utilising 3D Images for the Virtual Assessment of Patients with Cutaneous T-Cell Lymphoma**
[Jillian Wells, MBBS \(Hons\)](#)
- J-02 WEKAnalysis: Machine Learning and Database Analysis for Classification of CTCL Patients versus Controls**
[Emily R. Gordon, BA](#)
- J-03 Innovative Identification of Sézary Cells: A Transcriptome-based Approach to Clonal Variability and Distinct Phenotypes**
[Oleg E. Akilov, MD, PhD](#)
- J-04 Computational Free Flow Cytometry for Sézary Cells Identification and Quantification**
[Hélène Moins, MD, PhD](#)
- J-05 Leveraging Deep Learning to Resolve Skin Lymphoma Using Highly Multiplexed Protein Fluorescent Imaging**
[Pacôme Prompsy](#)
- J-06 Hemophagocytic Lymphohistiocytosis Machine Learning Prediction in Subcutaneous Panniculitis-like T-Cell Lymphoma**
[Tho Ngoc-Quynh Le, MD](#)
- J-07 Identification of Distinct Gene Expression Profiles from Mycosis Fungoides Atopic Dermatitis, and Psoriasis Lesions Using a Non-invasive Skin Sampling Technique** [Heather W. Goff, MD](#)
- J-08 Gut Microbiome of Cutaneous T-Cell Lymphoma Patients is Altered Following Narrowband Ultraviolet-B Phototherapy and Exhibits Profiles that Predict Treatment Responsiveness** [William Nguyen, BS](#)
- J-09 T-Cell Receptor High-throughput Sequencing and TRBC1 Immunohistochemistry in the Evaluation of Persistent Cutaneous T-Cell Lymphoma in Mogamulizumab-associated Rash** [Andrea P. Moy, MD](#)


TRANSFORMING WELLNESS TOGETHER MOVEMENT

AI WELLNESS

BROUGHT TO YOU BY AI WELLNESS AT THE 5TH WORLD CONGRESS OF CUTANEOUS LYMPHOMAS!

More than a health tech company, AI Wellness is a revolutionary platform connecting diverse modalities with AI technology that supports the 8 dimensions of Wellness. Enhance overall well-being with the latest innovations and educational resources, placing wellness at your fingertips.

EXPERIENCE WHAT AI WELLNESS OFFERS



Discover the AI Wellness Ecosystem

Constantly evolving, our ecosystem is driven by a commitment to innovation and excellence. Through continuous research, strategic partnerships, user feedback, and community engagement, we strive to improve the future of wellness technology.



MEDIA LOUNGE WITH AI WELLNESS TV

Dive into insights streamed on AI Wellness Mirrors, transforming idle moments into opportunities for growth and inspiration along with the option to create a digital twin for unlimited content creation.



AI WELLNESS MIRROR

Transform your healthcare experience with automated check-in, concierge services, and instant access to digital health resources.

The Launch of YESDOCTOR LOUNGE



Experience a gamified wellness journey where doctors vote for the best BioStacks to be launched in partnership hospitals. Enjoy curated Biostacks for a rejuvenating experience. Add a combination of Wellness and Nutrition by **Penny Foskaris**, an award-winning nutritionist, wellness innovator, and health and life coach. Expect a powerful focus on targeted cellular activation, total body circulation, enhanced light with sound therapy, and accelerated rejuvenation protocol through modalities to Relax, Reset, and Rejuvenate.

Join the Movement!

Experience the future of wellness with AI Wellness. Explore our innovative solutions and take your wellness journey to new heights. Don't miss out – seize the opportunity to transform your well-being today!

Generously Sponsored by



POSTERS

THERAPEUTICS/PRECLINICAL STUDIES

- 001 Efficacy of Mogamulizumab in Combination Therapy for Relapsed or Refractory Sézary Syndrome [Jordan Pilkington, BA](#)
- 002 Evaluation of Long-term Responses of Use of Chloromethine in Mycosis Fungoides [Silvia Alberti-Violetti, MD, PhD](#)
- 003 A Case Report on the Utilization of Excimer 308 nm Lamp Therapy in Treatment of Early-stage Mycosis Fungoides [Christina Asare, BS](#)
- 004 Mogamulizumab-induced Cardiotoxicity in Cutaneous T-Cell Lymphoma [Megan Trager, MD, MS](#)
- 005 Surgical Treatment for Cutaneous B-cell Lymphoma [Thais Buffo, MD](#)
- 006 Moga-stop Study: Outcome of Patients with Sézary Syndrome Treated with Mogamulizumab, after Treatment Discontinuation (Progression Excluded) [Martine Bagot, MD, PhD](#)
- 007 Evolution of the First Cohort of Patients with Mycosis Fungoides and Sézary Syndrome Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation in Argentina [Paula Enz, MD](#)
- 008 Radiation Therapy Combined with Hematopoietic Stem Cell Transplantation for T-Cell Lymphomas [Savita Dandapani, MD, PhD](#)
- 009 Chloromethine Gel as Active and as Maintenance Treatment in Mycosis Fungoides Patients Stages IA IIB [Marios Koumourtzis, MD, MSc](#)
- 010 Trial in Progress: EORTC 1820 MOGAT – Mogamulizumab Plus Total Skin Electron Beam Therapy in Stage IB-IIB Cutaneous T-Cell Lymphoma [Pablo L. Ortiz-Romero, MD, PhD](#)
- 011 Intralesional Rituximab Therapy for the Treatment of Primary Cutaneous B-Cell Lymphoma: A Small Case Series [Jori Hardin, MD](#)

CHALLENGING CASES OF CUTANEOUS LYMPHOMAS

- 012 Concurrent Papular and Dyshidrotic Mycosis Fungoides in a Black Patient [Jori Hardin, MD](#)
- 013 Omental-predominant Subcutaneous Panniculitis-like T-Cell Lymphoma Simulating Peritoneal Carcinomatosis [Ben J. Friedman, MD](#)
- 014 The Development of Two Clonally and Histologically Distinct Subtypes of Extranodal B-Cell Lymphomas in the Brain and Skin in One Individual [Jenna Mandel, BS](#)
- 015 Widespread Visceral Metastasis in a Large Cell Transformed Mycosis Fungoides Patient in a Clinical Complete Cutaneous Response [Jennifer A. DeSimone, MD](#)
- 016 Lymphomatoid Papulosis with an Unusually Prominent B-Cell Population and Features of T Follicular Helper Phenotype [John S. Runge, MD, PhD](#)
- 017 Systemic Anaplastic Large Cell Lymphoma with Unbalanced DUSP22 Gene Rearrangement Exclusively Involving the Skin [John S. Runge, MD, PhD](#)
- 018 Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective: Case Report [Paula Enz, MD](#)
- 019 Epstein-Barr Virus Positive Mucocutaneous Ulcer and Atypical Mycobacteria Infection in an Immunosuppressed Patient Associated with Methotrexate [Paula Enz, MD](#)
- 020 Unexplained Persistent Transaminitis in a Patient with Sézary Syndrome [Caitlyn Myrdal, MD](#)
- 021 Mycosis Fungoides Presenting as Dermatomyositis: A Diagnostic Challenge [Jacqueline M. Junkins-Hopkins, MD](#)
- 022 From Atopy to Sézary Syndrome and Back Again: A Case Report of Sézary Syndrome Diagnosis Secondary to Dupilumab Use with Spontaneous Improvement after Dupilumab Cessation [Martha Lodyga, MD](#)
- 023 Mycosis Fungoides - A Story of Non-pruritic Rash Unveiling T-Cell Non-Hodgkin's Lymphoma [Neil Vuppala, BA](#)
- 024 The Spectrum of CD8+ Cutaneous T-Cell Lymphomas: Clinical, Histologic, and Phenotypic Variants [Madisen Swallow, MS](#)
- 025 Poikilodermatous Mycosis Fungoides in an 18-year-old Filipino Female [Cybill Dianne C. Uy, MD](#)
- 026 New Frontier: A Complex Case of a 65-year-old Filipino Male with Sézary Syndrome [Precious U. Imam, MD, DPDS](#)
- 027 Diffuse Large B-Cell Lymphoma of the Skin with Colonization of a Haemangioma Mimicking Intravascular Large B-Cell Lymphoma [Benjamin Ho, MBBS, MRCP](#)
- 028 Tumor Stage Mycosis Fungoides in a 5-year-old [Rishabh Lohray, BS](#)
- 029 Mycosis Fungoides in Pregnancy: Disease Activity and Outcomes [Rishabh Lohray, BS](#) (*Classification/Epidemiology/Prognostic Factors*)
- 030 Primary Cutaneous Epidermotropic, Cytotoxic, ALK+ T-Cell Lymphoma: Appraisal of a Discrete Pattern of Disease [Italo Francesco Aromolo, MD](#)

CLASSIFICATION/EPIDEMIOLOGY/PROGNOSTIC FACTORS

- 031 GATA3 Expression in CD4 Small/Medium-sized Pleomorphic Lymphoproliferative Disorder: Evaluation of T Follicular Helper Subsets [Italo Francesco Aromolo, MD](#)
- 032 Is Small-plaque Parapsoriasis the Right Term? Clinico-pathological Evaluation of 30 Cases [Italo Francesco Aromolo, MD](#)
- 033 Cutaneous T-Cell Lymphoma and Dupilumab Use: A Retrospective Matched Cohort Study of Clinical Characteristics and Treatment Outcomes [Robert Stuver, MD](#)
- 034 Updates on CTCL Diagnostic and Therapeutic Trends Amidst the COVID-19 Pandemic: Insights from an Italian Referral Center [Gabriele Rocuzzo, MD](#)
- 035 Preliminary Insights on Different Erythroderma Morphological Features: A Prospective Validation Study [Gabriele Rocuzzo, MD](#)
- 036 Changes to Mycosis Fungoides and Sézary Syndrome Clinical Trials after the 2011 Tri-societies Guidelines [Simon J. Gunter, MPhil](#)
- 037 Cutaneous Lymphoproliferative Disorders after COVID-19 Vaccination: Analysis of 50 International Cases [Emily R. Gordon, BA](#)
- 038 Passing Notes: Designing a Standardized CTCL Note Template Based on ISCL Expert Consensus [Emily R. Gordon, BA](#)
- 039 From Pause to Progression: Lessons for CTCL Maintenance Therapy from the COVID-19 Pandemic [Emily R. Gordon, BA](#)
- 040 Visceral Involvement in Cutaneous T-Cell Lymphoma: Clinical Characteristics and Outcomes [Sima Rozati, MD, PhD](#)
- 041 Mogamulizumab-associated Myasthenia Gravis: A Patient Report [Sima Rozati, MD, PhD](#) (*Challenging Cases of Cutaneous Lymphomas*)
- 042 Presentation and Outcomes of Cutaneous T-Cell Lymphoma Following the Use of Dupilumab Compared to Other Biologic Therapies [Sima Rozati, MD, PhD](#) (*Biologic Insights*)

CLASSIFICATION/EPIDEMIOLOGY/PROGNOSTIC FACTORS (CONT.)

- 043 Outcomes with Sequencing of Romidepsin Followed by Mogamulizumab for the Treatment of Cutaneous T-Cell Lymphomas
Emily R. Gordon, BA (Biologic Insights)
- 044 Cutaneous T-Cell Lymphoma Clinical Trial Enrollment and Reporting Demographics: A Systematic Review *Leore Lavin, MS*
- 045 US FDA Reports of Cutaneous T-Cell Lymphoma and Lymphoma-related Events Associated with Dupilumab *Leore Lavin, MS*
- 046 Clinicoprognostic Implications of Blood Eosinophilia and Tissue Eosinophil Infiltration in Mycosis Fungoides: A Retrospective Cohort Study
Woo Jin Lee, MD, PhD
- 047 Mycosis Fungoides and Associated Malignancies in a Dutch Nationwide Retrospective Cohort Study *Rosanne Ottevanger, MD*
- 048 Risk of Systemic Lymphoma in Patients with Cutaneous CD30+ Lymphoproliferative Disorder: A Single Center Retrospective Analysis
Michi Shinohara, MD
- 049 Histopathological Features of Mycosis Fungoides in a Cohort of Asian Children *Mark Jean-Aan Koh, MBBS*
- 050 Chemical Exposures and Demographic Associations in Cutaneous T-Cell Lymphoma: A Large Single Institution Physician Validated Cohort Study
Yanzhen (Janet) Pang, BS
- 051 Clinicopathological Features and Mortality in Patients Folliculotropic Mycosis Fungoides: A Retrospective Analysis *Kelly Meza, MD*
- 052 Granulomatous Mycosis Fungoides: A Retrospective Cohort Study *Samruddhi Arkatkar, BS*
- 053 Mogamulizumab for the Treatment of Cutaneous T-Cell Lymphoma: Characterization of Patients Achieving Skin Response *Rachel E. Christensen, MD*
- 054 Overall and Cause-specific Mortality Among Patients with Cutaneous T-Cell Lymphoma from the United States *Lauren Shea, MD*

TUMOR MICROENVIRONMENT

- 055 Prognostic Factors Based on the Tumor Microenvironment In Primary Cutaneous B-Cell Lymphoma: Retrospective Study of 216 Biopsies
Gabor Dobos, MD, PhD

PATHOGENESIS/BIOMARKERS

- 056 The Diagnostic Value of CD4+CD7-CD26- (Double-negative) T Cells from Flow Cytometry in the Diagnosis and Follow up of Mycosis Fungoides and Sézary Syndrome: A Prospective Study *Gabor Dobos, MD, PhD*
- 057 New Marker for the Diagnosis of Mycosis Fungoides *Ekaterina Dunaeva, MD*
- 058 The Use of Flow Cytometry of Skin Lesions as a Complementary Diagnostic Method for Cutaneous T-Cell Lymphoma *Rodrigo Cesar Davanco*

TRIALS IN PROGRESS

- 059 A Study of DR-01 in Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas *Kimberley Dilley, MD, MPH*
- 060 Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 in Patients with Advanced Malignancies with an Expansion Cohort Recruiting T-Cell Lymphoma Patients *H. Miles Prince AM, MBBS (Hons), MD*
- 061 Lymphatic Delivery of Pembrolizumab to Tumor Draining Lymph Nodes in Relapsed or Refractory Mycosis Fungoides *Russell Ross, PhD*
- 062 A Phase 1a/1b Trial of ST-001, a Fenretinide (4-HPR) Phospholipid Suspension for 4-hour Intravenous Infusion, in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma (NCT04234048) *Oleg E. Akilov, MD, PhD*

LEADING-EDGE RESEARCH AND FUTURE DIRECTIONS OF CUTANEOUS LYMPHOMAS

- 063 The Role of PET/CT in the Staging of Mycosis Fungoides and Sézary Syndrome *Jade Cury-Martins, MD, PhD*

MULTIPLE/MULTIPLE FOCUS AREAS

- 064 Subcutaneous Panniculitis-like T-Cell Lymphoma: A Diagnostic Challenge
Juliana Yumi Massuda Serrano, MD, MSc (Challenging Cases of Cutaneous Lymphomas)
- 065 If Purpuric Lesions, Think of Mycosis Fungoides *Juliana Yumi Massuda Serrano, MD, MSc (Challenging Cases of Cutaneous Lymphomas)*
- 066 Exuberant Primary Cutaneous Marginal Zone B-Cell Lymphoma with Orbital Invasion
Juliana Yumi Massuda Serrano, MD, MSc (Challenging Cases of Cutaneous Lymphomas)
- 067 Ichthyosiform Lesions: Think "Lymphomatously" *Juliana Yumi Massuda Serrano, MD, MSc (Challenging Cases of Cutaneous Lymphomas)*
- 068 Assessment of Infection Profile and Incidence of Other Malignant Neoplasms in Patients with Mycosis Fungoides and Sézary Syndrome
Juliana Yumi Massuda Serrano, MD, MSc (Quality of Life/Patient-Reported Outcomes)
- 069 Unexpected Evolution with Psoriasis and Atopic Dermatitis Treatments: The Need to Consider a Lymphoma
Juliana Yumi Massuda Serrano, MD, MSc (Quality of Life/Patient-Reported Outcomes)
- 070 Unusual Connection: Are There Links Between Pachydermatous Eosinophilic Dermatitis and Granulomatous Slack Skin?
Elisa Nunes Secamilli, MD (Challenging Cases of Cutaneous Lymphomas)
- 071 Nodular Skin Infiltrations – Pseudolymphoma vs. Lymphomatous Infiltration?
Elisa Nunes Secamilli, MD (Challenging Cases of Cutaneous Lymphomas)
- 072 Treatment of Bartonella Henselae Infection as a Modifying Factor of the Immune Response In Sézary Syndrome
Elisa Nunes Secamilli, MD (Challenging Cases of Cutaneous Lymphomas)
- 073 Clinical and Histological Differences Between Pediatric Pityriasis Lichenoides and Hypopigmented Mycosis Fungoides
Elisa Nunes Secamilli, MD (Challenging Cases of Cutaneous Lymphomas)
- 074 Incidence of Bartonella Sp. Bacteremia on Patients with Cutaneous T-Cell Lymphomas and Healthy Subjects: A Pilot Study
Elisa Nunes Secamilli, MD (Pathogenesis/Biomarkers)

INDUSTRY SATELLITE SYMPOSIA

SANOFI

Thursday, April 11, 2024

TIME: 6:45 to 7:45 a.m.

ROOM: Ballroom C

An Innovative Treatment Option for Appropriate Patients With cGVHD

SPEAKER

[Amandeep Salhotra, MD](#)

Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

PROGRAM

6:45 to 7 a.m.	Breakfast and Arrivals
7 to 7:05 a.m.	Opening and Welcome (Kathy Collins, Sanofi)
7:05 to 7:40 a.m.	An Innovative Treatment Option for Appropriate Patients With cGVHD (Amandeep Salhotra, MD)
7:40 to 7:45 a.m.	Q&A and Closing (Amandeep Salhotra, MD)

HELSINN

Thursday, April 11, 2024

TIME: 12:45 to 1:45 p.m.

ROOM: Ballroom C

Treating Stage IA/IB MF-CTCL: Reviewing Recent Clinical Data

SPEAKER

[Oleg E. Akilov, MD, PhD](#)

Assistant Professor; Director, Cutaneous Lymphoma Program and Extracorporeal Photopheresis Unit; University of Pittsburg

PROGRAM

12:45 to 1 p.m.	Lunch and Arrivals
1 to 1:05 p.m.	Opening and Welcome
1:05 to 1:40 p.m.	Treating Stage IA/IB MF-CTCL: Reviewing Recent Clinical Data (Oleg E. Akilov, MD, PhD)
1:40 to 1:45 p.m.	Q&A and Closing (Oleg E. Akilov, MD, PhD)

KYOWA KIRIN

Friday, April 12, 2024

TIME: 11:45 a.m. to 12:45 p.m.

ROOM: Ballroom C

Dodging the Pitfalls of Diagnosing Cutaneous T-Cell Lymphoma (CTCL)


SPEAKER

[Alejandro A. Gru, MD](#)

Leonard C. Harber Professor of Dermatology; Director of Dermatopathology; Columbia University Irving Medical Center

PROGRAM

11:45 a.m. to 12 p.m.	Lunch and Arrivals
12 to 12:40 p.m.	Dodging the Pitfalls of Diagnosing Cutaneous T-Cell Lymphoma (CTCL) (Alejandro A. Gru, MD)
12:40 to 12:45 p.m.	Q&A and Closing (Alejandro A. Gru, MD)



INNOVATION IN
**CUTANEOUS T-CELL
LYMPHOMA (CTCL)**



**Focused on improving the
lives of patients all over
the world**



We are inspired by the strength of this community and proud to support your journey in making a...

profound impact.

To learn more about us and our commitment to the community, please visit kkna.kyowakirin.com.





KYOWA KIRIN

THIS IS **LIVING WITH CANCER**™

This Is Living With Cancer™ is a program for people living with cancer and those who love them. We provide support and resources for all, with a growing focus on underserved communities who experience challenges in access to care.

GET IT DONE

Cancer screenings and follow-ups can't wait

Find tools to help guide conversations with your doctor.

LIVE WELL

Nutrition and wellness tips

Learn about healthy living and find resources to help you manage your mental health.

AS WE AGE

Resources for adults 65+ and their loved ones

Discover how to become your best advocate.

THIS IS FOR YOU

Support designed with you in mind

Develop skills to help you cope with challenges.

Find tools to help live life beyond your diagnosis at


[ThisIsLivingWithCancer.com](https://www.thisislivingwithcancer.com)




© 2023 Pfizer Inc.

All rights reserved.

PP-UNP-USA-2315-02



Mallinckrodt



VISIT US AT OUR EXHIBIT

Mallinckrodt, the "M" brand mark and the Mallinckrodt logo are trademarks of a Mallinckrodt company.
© 2024 Mallinckrodt. US-2400091 02/24

ABSTRACT PRESENTER INDEX

A

Wei Ai, MD, PhD	F-01
Oleg E. Akilov, MD, PhD	D-06, J-03, 062
Neha Akkad, MD	H-06
Silvia Alberti-Violetti, MD, PhD	A-10, G-10, 002
Pamela Blair Allen, MD, MSc	A-14, E-04
Florent Amatore, MD, PhD	I-03
Iris Amitay-Laish, MD	I-05
Samruddhi Arkatkar, BS	052
Italo Francesco Aromolo, MD	030, 031, 032
Christina Asare, BS	H-01, 003

B

Martine Bagot, MD, PhD	006
Farrah Bakr, MBBS, PhD	F-03
Tarek Bandali, MD	G-12
Emilio Berti, MD	A-16
Odette Buelens, BN, MANP-NP	H-08
Thais Buffo, MD	005

C

Victoria Campbell, MSci, Mres	C-03
Simon Cao, MPH	C-05
Michael Cao, MBBS	H-03
Yun-Tsan Chang, PhD	C-08
Caroline Chen, BA	F-05
Melissa Cheng, BS	I-06
Sumanth Chennareddy, BA	D-10
Lauren Chrisman, BA	A-01, E-08
Rachel E. Christensen, MD	053
Joseph Cleveland, MD	D-01
Leah Cohen, MD	I-04
Emry Cohenour, MS	C-01
Richard Cowan, MD	H-04
Liliana Crisan, MD	D-02
Jade Cury-Martins, MD, PhD	G-09, 063

D

Savita Dandapani, MD, PhD	008
Rodrigo Cesar Davanco	058
Jennifer A. DeSimone, MD	015
Kimberley Dilley, MD, MPH	059
Gabor Dobos, MD, PhD	F-04, 055, 056
Liam Donnelly, MD	C-02
Ekaterina Dunaeva, MD	057

E

Paula Enz, MD	007, 018, 019
---------------	---------------

F

Francine M. Foss, MD	G-08, G-15
Ben J. Friedman, MD	013

G

Shamir Geller, MD	F-12
Michael Girardi, MD	G-04
Heather W. Goff, MD	J-07
Emily R. Gordon, BA	J-02, 037, 038, 039, 043
Simon J. Gunter, MPhil	036

H

Zhen Han, PhD	E-03
Jori Hardin, MD	011, 012
Benjamin Ho, MBBS, MRCP	027
Ryoma Honda, MD	E-05
Madeline J. Hooper, MD	E-07

I

Precious U. Imam, MD, DPDS	026
----------------------------	-----

J

Courtney M. Johnson, MD, PhD	E-12
Jacqueline M. Junkins-Hopkins, MD	I-08, 021

K

Ariel Karwat, BSN, MSN-AGNP	F-08
Werner Kempf, MD	A-17
Juliette Kersten, MD	B-03
Michael Khodadoust, MD, PhD	G-02
Youn H. Kim, MD	F-07
Mark Jean-Aan Koh, MBBS	H-07, 049
Marios Koumourtzis, MD, MSc	009
Miki Kume, MD, PhD	C-10

L

Brigit A. Lapolla, BS	H-09, H-10
Leore Lavin, MS	044, 045
Tho Ngoc-Quynh Le, MD	J-06
Robert E. LeBlanc, MD	I-10
Woo Jin Lee, MD, PhD	E-09, 046
Ziqi Liu, MD	I-11
Martha Lodyga, MD	022
Rishabh Lohray, BS	A-11, I-02, 028, 029

ABSTRACT PRESENTER INDEX CONT.

M

Jenna Mandel, BS	014
Nina Martins, BA	I-09
Juliana Yumi Massuda Serrano, MD, MSc	064, 065, 066, 067, 068, 069
Susanne Melchers, MD	F-06
Kelly Meza, MD	051
Christina Mitteldorf, MD	A-08, G-14
Tomomitsu Miyagaki, MD, PhD	A-09
Denis Miyashiro, MD, PhD	A-05
Hélène Moins, MD, PhD	J-04
Kevin Molloy, MB, PhD	H-05
Daniel Montezzo, MD, PhD	E-10
Andrea P. Moy, MD	J-09
Duncan Murray, MBChB, PhD	E-02
Caitlyn Myrdal, MD	020

N

William Nguyen, BS	A-07, J-08
Jan Nicolay, MD, MSc	G-13
Pia Rude Nielsen, MD, PhD	I-12
Neda Nikbakht, MD, PhD	E-11
Elisa Nunes Secamilli, MD	070, 071, 072, 073, 074

O

Francesco Onida, MD	G-07
Pablo L. Ortiz-Romero, MD, PhD	010
Rosanne Ottevanger, MD	047

P

Yanzhen (Janet) Pang, BS	A-04, D-09, 050
Evangelia Papadavid, MD, PhD	E-01, E-06
Jongbin Park, MD, PhD	A-12
Jacqueline Payton, MD, PhD	D-05
Brandy Phan, BSA	A-03
Monika Pieniawska, MSc	C-04
Jordan Pilkington, BA	001
H. Miles Prince AM, MBBS (Hons), MD	G-11, 060
Pacôme Prompsy	J-05
Melissa Pulitzer, MD	D-04
Seda Purnak, MD	A-13

Q

Pietro Quaglino, MD	B-02
Christiane Querfeld, MD, PhD	G-01

R

Ziba Rahbar, MD, MPH	A-15
Karolina Rassek, PhD	D-03
Jack Reid, MD	I-01
Katharina Rindler, PhD	D-08
Nathan Roberts, MD	G-03
Gabriele Rocuzzo, MD	F-09, 034, 035
Andrea Roggo, MD	D-07
Russell Ross, PhD	061
Sima Rozati, MD, PhD	A-06, 040, 041, 042
John S. Runge, MD, PhD	016, 017

S

Julia Scarisbrick, MBChB, MD	B-01, F-10, H-02
Tarsheen Sethi, MD, MS	F-13
Lauren Shea, MD	054
Michi Shinohara, MD	048
Rudolf Stadler, MD, PhD	F-11
Robert Stuver, MD	033
Madisen Swallow, MS	024

T

Megan Trager, MD, MS	004
----------------------	-----

U

Cybill Dianne C. Uy, MD	025
-------------------------	-----

V

Neil Vuppala, BA	023
------------------	-----

W

Jennifer Wang, MD	C-06
Jillian Wells, MBBS (Hons)	J-01
Wen-Kai Weng, MD, PhD	G-05, G-06
Rebekah Wieland, MD, MS	C-09
Rein Willemze, MD	A-02

Y

Henry Yang, BS	I-07
----------------	------

Z

Xu Hannah Zhang, PhD	F-02
Yumeng (Julia) Zhang, MD	C-07

